Stockmoney Lizards Newsletter - Issue #8

Editorial

Dear fellow stockmoney hunters and crypto lovers!

The past week at crypto and stock markets was very interesting once again. Both #Altcoins and #Bitcoin saw a setback and are currently trading at crucial support levels as we are writing. Besides this little setback with regards to current price levels the fundamental implementation of #Bitcoin going mainstream continues. Many retail stores are now accepting #Bitcoin, more and more countries are pushing Bitcoin and considering to make it a legal tender now. The amount of active Bitcoin addresses increases steadily. Or to make it short: The demand further increases while the supply remains limited.

Last week, everyone was clearly focussing on this year's Bitcoin conference 2022 - a huge gathering for Bitcoiners. And there were some really interesting insights about where the near future may bring us. One being the further implementation of the lightning network that will further improve Bitcoin payments and transactions. Altcoins haven't boosted yet either - #Altscoineason 2022 waits to be finally initiated.  

The biotech sector is stabilizing. Among last week's regulatory news, the FDA on Monday notified Alnylam Pharmaceuticals of delay in reviewing its New Drug Application for the amyloidosis drug vutrisiran. The U.S. Centers for Medicare & Medicaid Services (CMS) wants to limit coverage for Biogen's Alzheimer's drug Aduhelm. Troubled U.S. biotech Bluebird Bio announced a major restructuring program last Tuesday. AstaZenecas AZD8233, an investigational antisense oligonucleotide (ASO), met the primary endpoint with 73% reduction in low-density lipoprotein cholesterol (LDL-C) levels from baseline in the ETESIAN phase 2b trial.

Our sample portfolio is currently gaining speed! 3.8% since February and our top performer 14.3%! And many of our positions are just warming up. We have added another position last week.

Enjoy reading & stay tuned

Yours,

Stockmoney Lizards